JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

169.88 1.41

Résumé

Variation du prix de l'action

24h

Actuel

Min

166.98

Max

169.89

Chiffres clés

By Trading Economics

Revenu

-332M

-277M

Ventes

-11M

994M

Marge bénéficiaire

-27.816

Employés

18,300

EBITDA

730K

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+16.2% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.2B

9.2B

Ouverture précédente

168.47

Clôture précédente

169.88

Sentiment de l'Actualité

By Acuity

100%

0%

339 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 19:19 UTC

Acquisitions, Fusions, Rachats

Intertek Group Rejects EQT's Revised Offer

24 avr. 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Scoring the Cook Era -- Barrons.com

24 avr. 2026, 20:51 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 avr. 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:09 UTC

Résultats

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 avr. 2026, 19:48 UTC

Market Talk
Principaux Événements d'Actualité

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 avr. 2026, 19:22 UTC

Résultats

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 avr. 2026, 19:06 UTC

Résultats

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 avr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 avr. 2026, 18:30 UTC

Acquisitions, Fusions, Rachats

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 avr. 2026, 18:28 UTC

Acquisitions, Fusions, Rachats

Intertek Rejects Revised EQT Offer

24 avr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 avr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 avr. 2026, 17:42 UTC

Résultats

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 avr. 2026, 17:28 UTC

Résultats

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 avr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 avr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 avr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 avr. 2026, 17:09 UTC

Market Talk
Résultats

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 avr. 2026, 17:09 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 17:06 UTC

Résultats
Acquisitions, Fusions, Rachats

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 avr. 2026, 16:51 UTC

Résultats
Acquisitions, Fusions, Rachats

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

24 avr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

16.2% hausse

Prévisions sur 12 Mois

Moyen 197.3 USD  16.2%

Haut 235 USD

Bas 160 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

7

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

339 / 348Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat